Cargando…
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
BACKGROUND: Galcanezumab, along with three other monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, represents the latest disease-specific and mechanism-based treatment for the prophylaxis of migraine. Galcanezumab shares data also for the prophylaxis of cluster head...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222235/ https://www.ncbi.nlm.nih.gov/pubmed/32426040 http://dx.doi.org/10.1177/1756286420918088 |